Skip to main content
Premium Trial:

Request an Annual Quote

Bluestar Genomics: David Mullarkey

Early cancer detection company Bluestar Genomics has appointed David Mullarkey as CEO. He will also join the company's board of directors. Current acting CEO and CSO Samuel Levy will continue in his role as CSO.

Mullarkey most recently served as president and CEO of DNA sequencing company Omniome, which was acquired by Pacific Biosciences in 2021. Prior to Omniome, Mullarkey served as president and chief operating officer of Ariosa Diagnostics, which was acquired by Roche in 2014. Mullarkey has also held leadership positions at Johnson & Johnson, Eli Lilly, Valeant Pharmaceuticals, and Dow Pharmaceutical Sciences.

The Scan

Sensor to Spot SARS-CoV-2 Exposure

Yale researchers have developed a sensor that gauges SARS-CoV-2 exposure, according to the New Haven Register.

Watching BA.2

A subtype of the Omicron SARS-CoV-2 variant has been found in a number of countries, the Washington Post says.

Vermont Weighs Genetic Discrimination Bill

VT Digger reports Vermont legislators are considering a bill to bar insurer from denying customers coverage based on genetic information.

PNAS Papers on Convergent Pathogen Effectors, Lineage-Related RNA Mutations, Desiccation-Tolerant Grass

In PNAS this week: convergent evolution of pathogen effectors, algorithm to identify cell lineage features, and more.